NSE · Basic Materials · Specialty Chemicals
with an average price target of ₹1,279.17.
| Holder | Stake |
|---|---|
| Milan R Thakkar | 14.41% |
| Jayeshkumar Virendrabhai Patel | 3.64% |
| Jainam Broking Limited | 3.28% |
| Vikasa India Eif I Fund | 2.31% |
| Thakkar Nileshkumar Farshuram (HUF) | 1.54% |
| Document | Date |
|---|---|
| Q1 FY27 earnings call ANUPAM RASAYAN INDIA LIMITED – Q1 FY27 SUMMARY HEADLINE NUMBERS • Consolidated Total Income: INR 668 crores, up 36% year-on-year • Revenue from Oper | 2026-08-20 |
| Investor presentation · Q1 FY27 ANUPAM RASAYAN INDIA LTD — Q1 FY27 INVESTOR SUMMARY HEADLINE NUMBERS • Consolidated Total Revenue: ₹6,675 Mn | Y-o-Y growth: 36% • Consolidated EBIT | 2026-08-14 |
| Quarterly results · Q1 FY27 ANUPAM RASAYAN INDIA LTD – Q1 FY27 SUMMARY HEADLINE NUMBERS • Total Revenue Q1FY27: Rs 6,675 Mn (up 36% YoY from Rs 4,907 Mn in Q1FY26) • EBITDA (in | 2026-08-14 |
| Q4 FY26 earnings call ANUPAM RASAYAN INDIA LIMITED – Q4 FY26 SUMMARY HEADLINE NUMBERS • Consolidated Revenue FY26: INR 2,384 crores (up 65% Y-o-Y from INR 1,448 crores in | 2026-05-30 |
| Investor presentation · Q4 FY26 ANUPAM RASAYAN INDIA LIMITED – BLISS GVS PHARMA ACQUISITION SUMMARY HEADLINE NUMBERS • Bliss GVS Pharma Revenue (FY26): Rs 927 crore • Bliss GVS Pha | 2026-05-23 |
| Quarterly results · Q4 FY26 ANUPAM RASAYAN INDIA LTD. – FINANCIAL RESULTS SUMMARY Q4 & FY26 (Year Ended March 31, 2026) --- HEADLINE NUMBERS • FY26 Total Revenue: Rs 23,836 Mn | 2026-05-23 |
| Investor presentation | 2026-05-23 |
| Q3 FY26 earnings call ANUPAM RASAYAN INDIA LTD – Q3 FY26 EARNINGS SUMMARY HEADLINE NUMBERS • 9M FY26 consolidated revenue: INR 1,730 crores, up 84% year-on-year • 9M FY26 | 2026-02-19 |
Readable in the app.
| Action | Detail | Date |
|---|---|---|
| Dividend | ₹1.50 / share ex-date Sep 18, 2026 | 2026-09-18 |
| Announcement | Date |
|---|---|
| Update on acquisition of equity shares in Bliss GVS Pharma Anupam Rasayan India Limited announced a clarification to its previous disclosure regarding the acquisition of Bliss GVS Pharma Limited. The company completed the transaction on September 28 | 2026-09-30 |
| Acquisition of equity shares in Bliss GVS Pharma Limited Anupam Rasayan India Limited has successfully completed the acquisition of Bliss GVS Pharma Limited, gaining 47.95% stake through a share purchase agreement. Combined with 1,699 shares acqui | 2026-09-29 |
| Acquisition of Bliss GVS Pharma completed, third strategic step Anupam Rasayan India Limited has completed its acquisition of a 48.2% controlling stake in Bliss GVS Pharma Limited for ₹299 per share. This is the company's third major strategic acquisitio | 2026-09-28 |
| Acquired equity shares in Tanfac Industries through preferential issue Anupam Rasayan India Limited has completed the acquisition of 2,60,065 equity shares in Tanfac Industries Limited through a preferential issue (private placement). The company invested Rs. 6 | 2026-09-09 |
| Acquisition of equity shares in Tanfac Industries Limited via preferential issue Anupam Rasayan India Limited has approved the acquisition of 2,60,065 equity shares (0.73% stake) in its subsidiary Tanfac Industries Limited through a preferential issue at Rs. 2,341 per sh | 2026-09-07 |
Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Anupam Rasayan India Limited — free to start.
Open in the appGoogle PlayApp StoreData updated 2026-10-18.